South Africa: Committee on Health Receives Inputs on Tobacco Bill from Lesedi Black Business Forum and World Vapers Alliance
The LBBF supported the objectives of the Bill but called for a balance between public health and economic considerations. It said it has interacted with the Department of Health, via an online workshop organised by the department in 2020 but the LBBF is disappointed that the issues it raised in that workshop are not reflected in the final draft Bill submitted to Parliament.
On regulation, it said it supports efforts to reduce smoking in South Africa. Mr Lobi of the LBBF said a smarter, more practical approach is required to achieve the Bill's goal while avoiding harm to communities and businesses in the process. He urged the government to focus more on stopping the out-of-control illicit tobacco trade, which harms young people and the poor the most.
The LBBF said the government should work on preventing young people from smoking by using behavioural and educational programmes, as was done in the past with HIV/Aids awareness campaigns, for instance. These programmes are key to finding a lasting solution to reducing smoking.
Mr Lobi said: 'We have a problem with the criminalisation of smokers. Treating smokers as criminals is unfair and ineffective, and we encourage a more supportive approach to help them quit.'
The LBBF emphasised that in their local municipality, tobacco manufacturing is an anchor industry but it is being jeopardised by the Bill, should it be adopted as it is. Mr Lobi added: 'Beyond specific Lesedi consideration, the Bill fails to account for the commercial interests of small traders that dot the South African landscape due to lack of employment opportunities.'
The WVA is concerned that the Bill equates vaping with smoking. Provisions such as flavour bans, advertising restrictions, plain packaging and public use bans exacerbate the situation. Overregulation may drive consumers back to smoking or the illicit market. Notably, WVA said the Bill fails to acknowledge vaping as a tool for harm reduction. The WVA in its briefing submitted evidence from Sweden, demonstrating a remarkable 55% decline in smoking rates over the past decade.
Committee chairperson Dr Sibongiseni Dhlomo said inputs made during the public engagement process will be taken into consideration and applied when the committee starts its deliberation on the Bill after consultations with the public are completed.
The objective of the Bill is to strengthen public health protection measures, align South African tobacco control law with the World Health Organisation Framework Convention on Tobacco Control, and repeal the Tobacco Control Act of 1993 and its amendments.
Key provisions in the Bill include the introduction of 100 percent smoke-free indoor public places and certain outdoor areas; a ban on the sale of cigarettes through vending machines; the implementation of plain packaging with graphic health warnings; a ban on the display of products at points of sale; and the regulation and control of electronic nicotine delivery systems and non-nicotine delivery systems.
Distributed by APO Group on behalf of Republic of South Africa: The Parliament.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Zawya
5 hours ago
- Zawya
South Africa: Eastern Cape floods cause $282mln in damage – health facilities among worst hit
Homes, roads, bridges, schools and clinics were swept away as floods tore through the Eastern Cape — causing damage estimated at R5bn, with health facilities among the hardest hit. The Eastern Cape government says it will need at least R88m to repair hospitals and clinics damaged during the disaster. The province's Co-operative Governance and Traditional Affairs (Cogta) department confirmed that 63 healthcare facilities sustained damage in the deluge. The severe weather, which struck 38 days ago, caused widespread destruction across the Alfred Nzo, Chris Hani, Joe Gqabi and Sarah Baartman municipalities, while the OR Tambo and Amathole districts were the most severely affected. Providing an update from Mthatha on Wednesday, 17 July 2025 Cogta MEC Zolile Williams said recovery and disaster-response efforts were underway, with health infrastructure forming a key focus due to the level of destruction. 'Repairs will cost approximately R88m,' said Williams. 'Immediate repair work has already started at some facilities, and primary healthcare services have continued to reach the hardest-hit communities.' Williams added that a comprehensive assessment and verification of infrastructure damage had been completed by technical teams, paving the way for targeted recovery operations. All rights reserved. © 2022. Provided by SyndiGate Media Inc. (


Zawya
6 hours ago
- Zawya
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: announced that Shanghai Healthcare M&A Fund ("the M&A Fund") intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D capabilities. Dual-Driven Strategy: "Commercialization + Innovation" to Build a Leading Vaccine Ecosystem The vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine – stands as China's first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry ecosystem. Twin-City Collaboration: Combining "R&D + Manufacturing" to Create a New Industrial Framework This acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai's advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological's integration with Shanghai's R&D and clinical networks, creating an end-to-end collaborative system that spans from "clinical R&D to commercialization" and accelerates the development of a full industrial value chain. Dual-Channel Empowerment: Driving Corporate Value through "M&A + Integration" "This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading," commented Li Chen, Co-President of the M&A Fund."This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological's technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector." Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund The issuer is solely responsible for the content of this announcement. About Shanghai Healthcare M&A Fund A core component of Shanghai's state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai's biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs "anchor" companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors. About Chengdu Kanghua Biological Products Co., Ltd. Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China's National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies. SIIC Capital


Zawya
7 hours ago
- Zawya
Dubai Health Authority welcomes 20 global health leaders
The Dubai Health Authority (DHA) has welcomed a delegation of 20 senior healthcare leaders from various countries around the world, as part of its participation in the International Programme for Health Leadership. The programme is organised by the Government Experience Exchange Office (GEEO), under the Ministry of Cabinet Affairs, to exchange global best practices in healthcare and strengthen institutional knowledge partnerships. The delegation was introduced to Dubai's pioneering experience in advancing the healthcare sector and the significant achievements made in sustainability and the quality of care, reflecting the emirate's elevated global standing in public health and quality of life indices. During the meeting, DHA teams presented key aspects of the institutional transformation currently underway within Dubai's healthcare system, along with the emirate's health sector strategy. The session also covered the public health protection framework and the mechanisms for prevention and epidemic response. A detailed presentation was delivered outlining the authority's efforts to promote community health, strengthen preventive readiness, and ensure the integration of legislative and regulatory infrastructure in this domain. The teams also showcased the healthcare regulatory frameworks adopted in Dubai, along with the advanced standards and policies that reflect the authority's strategic approach and future vision for regulating healthcare professions and facilities across the emirate. The presentation further highlighted the integrated health insurance system and the sustainable financing mechanisms that contribute to the continuity and financial efficiency of healthcare services. The meeting also featured a specialised presentation on the findings of Dubai's Household Health Survey, emphasising the critical role of accurate data in supporting decision-making and enhancing planning based on scientific research and analytical insights. The delegation also undertook a field visit to the Dubai Health Authority's Crisis and Disaster Management Centre, where they received a detailed briefing on the emirate's emergency health management system. The session highlighted DHA's efforts to ensure maximum responsiveness during crises and disasters, as well as the centre's advanced capabilities. Dr. Alawi AlSheikh-Ali, Director-General of DHA, affirmed that the rapid progress in Dubai's healthcare sector has played a key role in reinforcing the emirate's position as a global leader in quality of life and healthcare.